Evidence supporting the use of: DHA (docosahexaeonic acid)
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

DHA (docosahexaenoic acid) is an omega-3 polyunsaturated fatty acid found abundantly in the brain and is vital for normal brain function. The rationale for using DHA in Parkinson’s Disease (PD) is primarily based on its neuroprotective and anti-inflammatory properties. Preclinical studies, including animal models of PD, have shown that DHA supplementation can reduce dopaminergic neuron loss, oxidative stress, and neuroinflammation—key features in the progression of PD. Furthermore, some observational studies in humans have found that higher dietary omega-3 intake is associated with a reduced risk of developing Parkinson’s Disease. However, direct clinical evidence in humans is limited.

A handful of small clinical trials have explored omega-3 fatty acids, including DHA, as adjunctive therapy in PD patients. These studies suggest potential benefits such as modest improvement in depressive symptoms and quality of life, but effects on core motor symptoms of PD are inconsistent or minimal. Systematic reviews and meta-analyses generally conclude that while there is a biological rationale and supportive evidence from animal studies, robust clinical trials demonstrating clear efficacy in humans are lacking. Consequently, DHA is sometimes recommended as an adjunct for its general brain health benefits but not as a primary therapy for PD.

In summary, while there is a scientific rationale and some preliminary evidence for DHA’s neuroprotective effects in PD, definitive clinical validation is lacking, and evidence strength is modest (rated 2/5).

More about DHA (docosahexaeonic acid)
More about Parkinson's Disease